Careers  |  Sign In  |  Register  |   Twitter

Vytorin Study

No significant reduction in atherosclerotic-plaque progression

The U.S. FDA issued an Early Communication regarding the agency’s ongoing review of Vytorin based on preliminary results from a recently completed study.

References and Resources
FDA Issues Early Communication about an Ongoing Review of Vytorin